Scarica l'app Stockscreener
4.06
4.10%
0.16
Dopo l'orario di chiusura:
4.14
0.08
+1.97%
Opus Genetics Inc Borsa (IRD) Ultime notizie
IRD Reiterated by Citizens -- Price Target Maintained at $11.00 - GuruFocus
Citizens reiterates Opus Genetics stock rating on development strategy By Investing.com - Investing.com Canada
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Opus Genetics (NASDAQ: IRD) registers 2.68M shares for resale by investors - Stock Titan
IRD Initiates Coverage by Guggenheim -- Rating Set to Buy - GuruFocus
Guggenheim Initiates Opus Genetics at Buy With $16 Price Target - Moomoo
Guggenheim Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $16 - Moomoo
Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD) - Seeking Alpha
IRD Q1 2026 Earnings: Significant Earnings Miss Amid Pre-Revenue Clinical Development StageBalance Sheet Strength - newsline.com
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts - marketscreener.com
Opus Genetics Slides Ahead of June Test - Bez Kabli
Opus Genetics touts retinal gene therapy pipeline, September BEST1 data catalyst - MSN
Opus Genetics Inc. (IRD) Q1 2026 Earnings: Steep EPS Miss and No Revenue, Yet Stock Climbs $3.81Estimate Dispersion - newsline.com
IRD News | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
Opus Genetics reports inducement grants under Nasdaq listing rule - marketscreener.com
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Gene therapy for blindness: Opus Genetics heads to Jefferies 2026 - Stock Titan
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - inkl
Leerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
IRD Initiates Coverage by Leerink Partners -- Rating 'Outperform' - GuruFocus
Leerink initiates Opus Genetics stock with outperform rating By Investing.com - Investing.com South Africa
Leerink Partners Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Opus Genetics stock with outperform rating - Investing.com
Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
Foundation Fighting Blindness Retinal Degeneration Fund Sells 1, - GuruFocus
Foundation fighting blindness fund sells $7.4m of Opus Genetics (IRD) stock - Investing.com Nigeria
Opus Genetics (IRD) investor files exit 13D after stake falls under 5% - Stock Titan
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
Opus Genetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IRD: Gene therapy pipeline advances with pivotal data and regulatory milestones expected in 2024 - TradingView
Lifesci Capital Predicts Lower Earnings for Opus Genetics - MarketBeat
Opus Genetics, Inc. (IRD) reports Q1 loss, misses revenue estimates - MSN
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - MarketBeat
Nantahala Capital (IRD) reports 4.84M shares; 3.16M exercisable within 60 days - Stock Titan
Perceptive (IRD) group holds 9.99% of Opus Genetics; warrants capped by limit - Stock Titan
Caligan Partners reports 8.5% stake in Opus Genetics (IRD) - Stock Titan
HC Wainwright Lifts Earnings Estimates for Opus Genetics - MarketBeat
Balyasny holds 5.11M shares in Opus Genetics (NASDAQ: IRD), includes warrants - Stock Titan
Cantor Fitzgerald Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Opus Genetics (NASDAQ:IRD) Stock Rating Lowered by Zacks Research - MarketBeat
Opus Genetics (IRD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $11 - Moomoo
IRD Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):